BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 33795234)

  • 1. Synthetic Lethality in Cancer Therapeutics: The Next Generation.
    Setton J; Zinda M; Riaz N; Durocher D; Zimmermann M; Koehler M; Reis-Filho JS; Powell SN
    Cancer Discov; 2021 Jul; 11(7):1626-1635. PubMed ID: 33795234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Link synthetic lethality to drug sensitivity of cancer cells.
    Wang R; Han Y; Zhao Z; Yang F; Chen T; Zhou W; Wang X; Qi L; Zhao W; Guo Z; Gu Y
    Brief Bioinform; 2019 Jul; 20(4):1295-1307. PubMed ID: 29300844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic lethality as an engine for cancer drug target discovery.
    Huang A; Garraway LA; Ashworth A; Weber B
    Nat Rev Drug Discov; 2020 Jan; 19(1):23-38. PubMed ID: 31712683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic lethality on drug discovery: an update on cancer therapy.
    Yar MS; Haider K; Gohel V; Siddiqui NA; Kamal A
    Expert Opin Drug Discov; 2020 Jul; 15(7):823-832. PubMed ID: 32228106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics.
    Bhattacharjee S; Nandi S
    IUBMB Life; 2017 Dec; 69(12):929-937. PubMed ID: 29171189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-omics characterization of synthetic lethality-related molecular features: implications for SL-based therapeutic target screening.
    Weng S; Ruan H
    FEBS J; 2023 Mar; 290(6):1477-1480. PubMed ID: 36461713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biology and Development of DNA-Targeted Drugs, Focusing on Synthetic Lethality, DNA Repair, and Epigenetic Modifications for Cancer: A Review.
    Watanabe K; Seki N
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality.
    Jerby-Arnon L; Pfetzer N; Waldman YY; McGarry L; James D; Shanks E; Seashore-Ludlow B; Weinstock A; Geiger T; Clemons PA; Gottlieb E; Ruppin E
    Cell; 2014 Aug; 158(5):1199-1209. PubMed ID: 25171417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
    Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
    Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLGNN: synthetic lethality prediction in human cancers based on factor-aware knowledge graph neural network.
    Zhu Y; Zhou Y; Liu Y; Wang X; Li J
    Bioinformatics; 2023 Feb; 39(2):. PubMed ID: 36645245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aurora kinase A, a synthetic lethal target for precision cancer medicine.
    Mou PK; Yang EJ; Shi C; Ren G; Tao S; Shim JS
    Exp Mol Med; 2021 May; 53(5):835-847. PubMed ID: 34050264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The power and the promise of synthetic lethality for clinical application in cancer treatment.
    Liu QW; Yang ZW; Tang QH; Wang WE; Chu DS; Ji JF; Fan QY; Jiang H; Yang QX; Zhang H; Liu XY; Xu XS; Wang XF; Liu JB; Fu D; Tao K; Yu H
    Biomed Pharmacother; 2024 Mar; 172():116288. PubMed ID: 38377739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.
    Topatana W; Juengpanich S; Li S; Cao J; Hu J; Lee J; Suliyanto K; Ma D; Zhang B; Chen M; Cai X
    J Hematol Oncol; 2020 Sep; 13(1):118. PubMed ID: 32883316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic analysis of the landscape of synthetic lethality-driven precision oncology.
    Schäffer AA; Chung Y; Kammula AV; Ruppin E; Lee JS
    Med; 2024 Jan; 5(1):73-89.e9. PubMed ID: 38218178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy.
    Schrempf A; Slyskova J; Loizou JI
    Trends Cancer; 2021 Feb; 7(2):98-111. PubMed ID: 33109489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens.
    Srivatsa S; Montazeri H; Bianco G; Coto-Llerena M; Marinucci M; Ng CKY; Piscuoglio S; Beerenwinkel N
    Nat Commun; 2022 Dec; 13(1):7748. PubMed ID: 36517508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To Discover the Efficient and Novel Drug Targets in Human Cancers Using CRISPR/Cas Screening and Databases.
    Onishi I; Yamamoto K; Kinowaki Y; Kitagawa M; Kurata M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling DNA trapping of anticancer therapeutic targets using missense mutations identifies dominant synthetic lethal interactions.
    Hamza A; Amitzi L; Ma L; Driessen MRM; O'Neil NJ; Hieter P
    Proc Natl Acad Sci U S A; 2021 Apr; 118(14):. PubMed ID: 33782138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-Cancer Analysis of Potential Synthetic Lethal Drug Targets Specific to Alterations in DNA Damage Response.
    Das S; Camphausen K; Shankavaram U
    Front Oncol; 2019; 9():1136. PubMed ID: 31709193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.